Five new reads underline a shift from “can we generate synthetic data?” to “can we justify using it?”—with rare disease, oncology, and inference validity as the pressure tests.
Data Augmentation and Synthetic Data Generation in Rare Disease Research: A Scoping Review
A PMC scoping review maps how rare-disease teams use augmentation and synthetic data to deal with small cohorts and heterogeneous phenotypes. The authors screened 2,864 candidate studies and highlight increased use of deep generative models since 2021, alongside rule-based approaches that remain attractive for interpretability but still require careful validation.
- Useful as a technique-selection checklist when sample sizes are too small for standard train/validate splits.
- Reinforces that “privacy-preserving” claims still need empirical utility and disclosure-risk testing.
- Signals growing expectations for ethical validation and regulatory alignment in biomedical synthetic data.
Generative Models for Synthetic Data: Transforming Data Mining in the GenAI Era
This arXiv tutorial surveys LLMs, diffusion models, and GANs for synthetic data in data mining, focusing on data scarcity, privacy, and annotation bottlenecks. It emphasizes practical workflows: generation strategies, evaluation methods, and where GenAI fits into existing pipelines rather than replacing them.
- Data leads can standardize evaluation (utility + privacy) instead of relying on “looks realistic” reviews.
- Helps teams decide when to synthesize labels versus features, reducing annotation costs without breaking governance.
Valid Inference with Imperfect Synthetic Data
Another arXiv paper targets a hard problem: drawing statistically valid inferences when synthetic data is imperfect (including LLM-generated data). It proposes a hyperparameter-free estimator based on generalized method of moments that combines real and synthetic samples, with reported empirical gains in low-data settings such as computational social science.
- Moves synthetic data from “training trick” toward defensible inference—critical for policy and human-subjects-adjacent work.
- Gives governance teams a path to document assumptions and guarantees when synthetic augmentation is used.
- Encourages mixed real+synthetic designs instead of all-synthetic datasets in sensitive domains.
Using generative AI to create synthetic data
Stanford Medicine describes RoentGen, an open model that generates synthetic X-rays from text prompts to address data gaps in rare diseases and uncommon conditions. The framing is pragmatic: synthetic images can support training for tasks like pneumonia or cardiomegaly detection while reducing reliance on real patient data.
- Imaging teams get a concrete synthetic modality (text-to-X-ray) to test augmentation versus privacy risk tradeoffs.
- Raises operational questions: prompt control, dataset shift, and how to audit synthetic artifacts before deployment.
Longitudinal Synthetic Data Generation by Artificial Intelligence to Address Data Fragmentation in Oncology
An ASCO Journals study looks at AI-generated longitudinal synthetic data to address oncology data fragmentation, scarcity, and privacy constraints. The core claim is that synthetic longitudinal datasets can enable analysis without exposing real patient information, offering an alternative to sharing sensitive records across institutions.
- Longitudinal synthesis is directly relevant to real-world evidence teams trying to link fragmented care journeys.
- Compliance leads can evaluate synthetic sharing as a complement to GDPR-era minimization and access controls.